US Stock MarketDetailed Quotes

ALEC Alector

Watchlist
  • 3.960
  • +0.020+0.51%
Close Nov 25 16:00 ET
  • 2.740
  • -1.220-30.81%
Pre 08:19 ET
387.81MMarket Cap-2315P/E (TTM)
Pre-Market
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Jaguar8
    Jaguar8
    16 hours ago
    NEWS
    $Alector (ALEC.US)$
    Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update
    Alector announced disappointing results from its INVOKE-2 Phase 2 trial of AL002 for early Alzheimer's disease. The drug failed to meet its primary endpoint of slowing disease progression and showed no significant effects on secondary endpoints or biomarkers. While AL002 achieved target engagement, it did not demonstrate treatment benefit...
    Jaguar8
    Jaguar8
    Sep 19 07:24
    NEWS
    $Alector (ALEC.US)$
    Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
    Alector (Nasdaq: ALEC) presented baseline characteristics for its pivotal INFRONT-3 Phase 3 clinical trial at the 14th International Conference on Frontotemporal Dementias. The trial evaluates latozinemab, a novel monoclonal antibody, for treating frontotemporal dementia with progranulin gene mutation (FTD-GR...
    Jaguar8
    Jaguar8
    Jul 28 07:06
    NEWS
    $Alector (ALEC.US)$
    Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
    Alector presented baseline characteristics for the INVOKE-2 Phase 2 clinical trial of AL002, a TREM2 agonist, at AAIC® 2024.
    The trial, involving 381 participants with early Alzheimer's disease (AD), is the first global Phase 2 study evaluating a TREM2 agonist's safety and efficacy in slowing AD progression.
    Key point...
    Moomoo AI
    Moomoo AI
    Jan 19 13:58
    Alector's low P/S ratio may be due to poor revenue performance and expectations of this trend continuing. Future revenue growth is expected to be significantly lower than the industry, possibly causing discomfort among shareholders and a drop in share price.
    Little Excitement Around Alector, Inc.'s (NASDAQ:ALEC) Revenues As Shares Take 27% Pounding
    Moomoo AI
    Moomoo AI
    Dec 12, 2023 06:41
    Arnon Rosenthal's major sale indicates insiders may expect a lower price. Despite high insider ownership, the absence of insider purchases and significant sales stirs uncertainty about the company's prospects and arouses investor caution.
    Alector Insiders Sell US$711k Of Stock, Possibly Signalling Caution
Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data